Table 4 Relevant pharmacogenetics association studies that focused on tryptophan hydroxylase 1 and 2 (TPH1 and TPH2)
From: Pharmacogenetics of antidepressant response: An update
Reference | Gene | Drug | Sample | Outcome measure | Results | p-value |
|---|---|---|---|---|---|---|
[55] | TPH1 | Citalopram | 105 subjects | HAMD | The remission rate was worse in A/A and A/C genotypes, even though the response rate did not differ between genotypes | p = 0.017 |
[56] | TPH1 | Various | 93 MDD patients and 127 controls | HAMD | No association either with depressive phenotype or with antidepressant response | Not significant |
[57] | TPH1 | Fluvoxamine or paroxetine | 221 MDD patients | HAMD | Lack of association | Not significant |
[48] | TPH1, TPH2 | Fluoxetine | 96 MDD patients | CGI | Three variations within the TPH1 differentiated responders from non-responders. Three variations in the TPH2 differentiated responders from specific and non-specific (fast antidepressant onset and lack of persistence) | 0.020 <p <0.042 |
[4] | TPH1 | Fluvoxamine | 217 MDD patients | HAMD | A/A genotype was associated with slower response (no pindolol) | p = 0.001 |
[58] | TPH1 | Paroxetine | 121 MDD patients | HAMD | A/A and A/C genotypes were associated with slower response (no pindolol) | p = 0.005 |